Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending May 2014. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility (PDMRs) under the GSK 401K plan.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure regarding director share allocations rather than a financial results report.
Material Changes
No material financial changes versus a prior comparable period are reported in this filing. The document details a specific increase in the notional allocation of American Depositary Shares (ADSs) within the GSK 401K plan.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies. It strictly reports a transaction notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(c).
Key Facts for Investors
- Transaction Date: May 9, 2014.
- Notification Date: May 12, 2014.
- Transaction Type: Increase in notional allocation of ADSs within the GSK 401K plan following a cash element revaluation.
- Price: $54.99 per ADS.
- Individuals Involved: Dr. M. Slaoui and Dr. K. Slaoui (Connected Person).
- Quantity: 3 ADSs allocated to the Connected Person.